S-1/A: Virpax Pharmaceuticals Seeks Up to $7 Million in New Offering Amidst Financial Challenges

Virpax Pharmaceuticals is offering up to 2,215,189 shares of common stock and accompanying warrants in a best efforts offering to raise capital for debt settlement, product development, and general corporate purposes, while facing Nasdaq compliance issues and ongoing litigation.

Summary

• Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, is offering up to 2,215,189 shares of common stock and accompanying warrants in a 'best efforts' offering.
• The assumed combined public offering price is $3.16 per share and accompanying warrant, based on the last sale price of the common stock on April 23, 2024.
• The company is also offering pre-funded warrants to purchasers who would otherwise exceed beneficial ownership limits of 4.99% or 9.99%.
• The offering will terminate on May 25, 2024, unless fully subscribed or terminated earlier.
• The company intends to use the net proceeds to pay $2.5 million related to a settlement agreement, fund product development, and for working capital.
• Virpax reported stockholders' equity of $1,934,321 in its Annual Report, falling below Nasdaq's minimum requirement of $2,500,000.
• Nasdaq has given Virpax until May 17, 2024, to submit a plan to regain compliance.
• The company is an emerging growth company and a smaller reporting company, allowing for reduced disclosure obligations.
• A settlement agreement with Sorrento and Scilex requires Virpax to pay $6 million, with $3.5 million already paid and $2.5 million due by July 1, 2024, plus royalties on certain product sales.
• The company is involved in ongoing litigation related to claims by Sorrento and Scilex.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the capital raise could provide necessary funds, the company faces financial challenges, Nasdaq compliance issues, and ongoing litigation, leading to a cautious sentiment.

Positives

• The offering provides capital to settle a significant portion of the Sorrento/Scilex debt.
• The funds raised will support ongoing product development activities.
• The company has exclusive global rights to several proprietary patented technologies.
• Virpax qualifies as an emerging growth company and a smaller reporting company, allowing for reduced disclosure obligations.

Negatives

• The company's stockholders' equity is below Nasdaq's minimum requirement, potentially leading to delisting.
• The company is involved in ongoing litigation, creating financial uncertainty.
• The offering is on a 'best efforts' basis, with no guarantee of raising the full amount.
• New investors will experience immediate and substantial dilution.
• There is no public market for the pre-funded warrants and common warrants being offered.
• The company has a limited operating history and has incurred significant operating losses.

Risks

• The company may not raise sufficient capital in this offering to meet its business goals.
• Failure to regain compliance with Nasdaq listing requirements could result in delisting.
• The company's management has broad discretion in using the net proceeds from the offering.
• The company will need additional future financing which may not be available on acceptable terms.
• The company is dependent on its product candidates, which are still in preclinical or early stages of clinical development.
• The company is dependent on third parties to manufacture its product candidates.
• The company may be required to use the proceeds from this offering to make payments for indemnification and/or damages related to litigation.

Future Outlook

The company expects to require an additional $11.0 million in order to file its IND for Probudur, including the $2.5 million that it is obligated to pay to the Plaintiffs.

Industry Context

Virpax is operating in the competitive pharmaceutical industry, focusing on novel drug delivery systems for pain management and CNS disorders, a market with increasing demand for non-opioid alternatives.

Comparison to Industry Standards

• Virpax is a preclinical-stage company, making direct comparison to revenue-generating pharmaceutical companies difficult.
• Comparable companies in the preclinical stage often rely on funding through equity offerings, partnerships, or grants.
• The success of Virpax will depend on the clinical trial outcomes and regulatory approvals of its product candidates, similar to other companies in the sector such as BioDelivery Sciences International and Heron Therapeutics, which focus on pain management.
• The company's focus on non-opioid pain management aligns with the industry trend towards safer alternatives, driven by the opioid crisis.

Legal Proceedings

• Virpax is involved in litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc.
• The company has reached a settlement agreement with Sorrento and Scilex, requiring a $6 million payment and royalties on certain product sales.
• The Court has requested supplemental briefing as to whether the Court can dismiss the Company from the lawsuit, as well as any claims Mr. Mack has against the Company arising from the Action.

Stakeholder Impact

• Shareholders will experience dilution from the offering.
• Employees' job security is tied to the company's financial stability and success in product development.
• Customers (potential patients) may benefit from the development of new pain management treatments.
• Suppliers and creditors face risks associated with the company's financial challenges.

Next Steps

• Virpax must submit a plan to Nasdaq by May 17, 2024, to regain compliance with listing requirements.
• The company will continue product development activities.
• The company will seek to close the offering by May 25, 2024.
• The company will make a $2.5 million payment to Sorrento and Scilex by July 1, 2024.

Key Dates

Keywords

offering, warrants, common stock, Virpax Pharmaceuticals, capital raise, Nasdaq, litigation, settlement, compliance, pharmaceutical, preclinical, funding